SAGESPRING WEALTH PARTNERS, LLC
Position in ALNY — Alnylam Pharmaceuticals, Inc.
CIK 2056425
FRANKLIN, TN
Position in ALNY
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$267,314
-$111,201 QoQ
Shares Held
888
-22.4% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#189
of 328 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ALNY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SAGESPRING WEALTH PARTNERS, LLC holds $3,585,996 across 9 Biotechnology names. ALNY ranks #3 (7.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,382 | $1,679,940 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
833 | $519,408 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
888 | $267,314 | |
| 4 | INCY |
Incyte Corp
|
2,037 | $230,914 | |
| 5 | RPRX |
Royalty Pharma plc
|
4,099 | $229,830 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
907 | $218,559 | |
| 7 | INSM |
INSMED Inc
|
2,031 | $216,545 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
1,141 | $213,686 |
All Filings in ALNY
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $267,314 | 888 | Shares | Sole | 2026-08-03 | |
| 2026-03-31 | $378,515 | 1,144 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $451,730 | 1,136 | Shares | Sole | 2026-01-07 | |
| 2025-09-30 | $586,872 | 1,287 | Shares | Sole | 2025-10-31 | |
| 2025-06-30 | $298,698 | 916 | Shares | Sole | 2025-07-28 | |
| No filing history on record for this holder in this stock. | ||||||